FC-009-V7953B15: Breakthrough Intranasal BTK Inhibitor Targeting Alzheimer's Disease Neuroinflammation

FC-009-V7953B15 is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor designed for intranasal delivery to treat Alzheimer's disease by modulating microglial neuroinflammation.

This comprehensive dataset includes Tier 1 computational validation (11/11 parameters passed with PERFECT scores), detailed synthetic routes, experimental protocols for Tier 2/3 validation, and comprehensive ADMET profiling across three independent computational platforms (ADMETlab 2.0, SwissADME, SwissTargetPrediction).

KEY FEATURES:• BBB Penetration: 99.2% (outstanding)• P-gp Efflux: 0.7% (minimal - excellent CNS exposure)• hERG Cardiotoxicity: 4.4% (excellent safety profile)• Synthetic Accessibility: 2.46/10 (very easy - 2-step route from commercial materials)• Drug-Likeness: 0 violations (perfect Lipinski/Veber compliance)• LogP Consensus: 2.0-2.4 (optimal for blood-brain barrier penetration)• Structural Novelty: Confirmed (distinct from existing BTK inhibitor patents)

COMPREHENSIVE DOCUMENTATION:• Complete synthetic procedures (step-by-step with reagents, conditions, characterization)• Tier 2 assay protocols (BTK IC50, hepatotoxicity, off-target screening, BBB validation, nasal tolerability)• Tier 3 study designs (kinase selectivity, PK/PD, GLP toxicology)• Target Product Profile (TPP) and development roadmap• Clinical rationale (BTK in Alzheimer's, intranasal delivery advantages)

CRITICAL LIMITATIONS ACKNOWLEDGED:• Hepatotoxicity prediction: 94.2% DILI probability (requires urgent experimental validation)• BTK IC50: Not yet measured (highest priority for Tier 2)• Off-target profile: 100 predicted targets identified (screening protocols provided)

Released under CC BY-NC-SA 4.0 for non-commercial academic research. Commercial licensing available via [e-mail].

VERSION: 1.0 (pkCSM mutagenicity and metabolic stability data to be added in version 1.1)